Clinical Trials
158 trialsTesting the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
National Cancer Institute (NCI)
NaliCap
Seoul National University Hospital
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
IMAGINE
University Hospital, Essen
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
Sun Yat-sen University
HOLIPANC
University of Cologne
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
FANTASTIC
Sun Yat-sen University
LOTS
National Cheng-Kung University Hospital
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
IDEA
GERCOR - Multidisciplinary Oncology Cooperative Group
FLEX
Amphia Hospital
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
HIPEC
National Cancer Institute, Naples
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
Zhujiang Hospital
FIND
Sixth Affiliated Hospital, Sun Yat-sen University
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Fujian Cancer Hospital
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
Tanta University
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
University of Southern California
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
Vastra Gotaland Region
Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
PEN-866 in Patients With Advanced Solid Malignancies
Tarveda Therapeutics
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
First Affiliated Hospital of Wenzhou Medical University
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
CSPC Ouyi Pharmaceutical Co., Ltd.
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Khon Kaen University
FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer
West China Hospital
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
Shanghai Zhongshan Hospital
nITRo
Centro Ricerche Cliniche di Verona
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
Sun Yat-sen University
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
National Cancer Centre, Singapore
RusGCG-01
Blokhin's Russian Cancer Research Center
IRIGA
Blokhin's Russian Cancer Research Center
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Shanghai JMT-Bio Inc.